Moleculin Biotech Inc buy stratec
Summary
This prediction ended on 20.12.18 with a price of €6.01. Massive losses of -40.00% were the result for the BUY prediction by stratec. stratec has 50% into this predictionMoleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Moleculin Biotech Inc | - | - | - | - |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by stratec for this prediction
In the thread Moleculin Biotech Inc diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
stratec stimmt am 20.12.2017 dem Buy-Gesamtsentiment mit dem Kursziel 8 $ zu.
Moleculin Biotech (NASDAQ:MBRX) initiated with Buy rating and $8 (373% upside) price target by Roth Capital.